Guest: Ilene Galinsky BSN,MSN,ANP-C

Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.

Host: Pam R. Taub, MD, FACC, FASPC

Guest: Sripal Bangalore, MD, MHA

For patients who have recently experienced a myocardial infarction, LDL cholesterol management is critical to help reduce the risk of recurrent CV events. At a time of the COVID-19 pandemic, when patient behavior and clinical practice methods are impacted, what can we do to improve CV outcomes for these patients? Join Drs. Pam Taub and Sripal Bangalore as they explore why patients with a recent myocardial infarction occurring within the previous 12 months are among the highest risk for recurrent CV events and what can be done to better manage that risk.

©2020 Amgen Inc. All rights reserved. USA-145-82480 12/20

Host: John J. Russell, MD

Guest: Philip J. Mease, MD

Guest: April Armstrong, MD, MPH

Of the more than eight million Americans living with psoriasis, up to 30 percent of them may go on to develop psoriatic arthritis (PsA). Dr. Philip Mease and Dr. April Armstrong are here to walk us through how physicians can provide multidisciplinary care for people living with this chronic condition. We’ll also hear from them about a treatment option available to adults with active PsA.

This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The consultants are paid speakers for Janssen Pharmaceuticals, Inc. The speakers are presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen.

© Janssen Pharmaceuticals, Inc. 2020 12/20 cp-187500v1

Host: Paul Doghramji, MD

Guest: Pavle Repovic, MD, PhD

There is no cure for relapsing multiple sclerosis (MS), a chronic and progressive disease in which disability accumulates over time, but available therapies may help modify the course by reducing disease activity. The MS specialist, Dr. Pavle Repovic, discusses KESIMPTA®, a treatment option offering adult RMS patients powerful efficacy with a demonstrated safety profile and flexible self-administration.

9/20 T-KSM-1393526

Guest: Timothy William West, MD

Here to discuss staying ahead of progression in patients with relapsing multiple sclerosis (RMS) is Dr. Timothy William West. Dr. West walks us through pathophysiological changes in progressing RMS patients, a patient case demonstrating why patients may experience increasing disability, and key data on MAYZENT®(siponimod), the first and only oral disease-modifying therapy studied and proven to delay disability progression in a more progressed RMS patient population, including active SPMS.

MAYZENT was evaluated in EXPAND—the largest Phase III study of secondary progressive MS (SPMS) patients to date (N=1651), which included a broad range of patients with moderate-to-advanced disability. Dr. West discusses clinical data from EXPAND including data of up to 5 years from a preplanned interim analysis of the EXPAND open-label extension study.

Guest: Matthew S. Davids, MD, MMSc

Guest: Andrew Souers, PhD

Apoptosis is a normal and highly regulated process that the body uses to dispose of aged or damaged cells. But what happens when this critical cellular process becomes impaired? Together, Drs. Andy Souers and Matt Davids answer that question and more, like how the protein BCL-2 regulates apoptosis and how venetoclax binds and inhibits BCL-2.

Host: John J. Russell, MD

Guest: Aaron Broadwell, MD

Guest: Michelle Owen, Clinic Operations Manager

Gaining access to treatment can be a complex process, and it is our job as healthcare professionals to help patients navigate through the steps and obtain the treatment they need. Dr. Aaron Broadwell and clinic operations manager Michelle Owen are here to discuss some of the common challenges patients face and things to consider when navigating the process.

The consultants are paid speakers for Janssen Pharmaceuticals, Inc. The opinions shared in this segment are those of the paid speakers and may not be reflective of the larger population.

© Janssen Pharmaceuticals, Inc. 2020 12/20 cp-185221v1

Host: Paul Doghramji, MD

Guest: Alex Spira, MD, PhD, FACP

Guest: John Longshore, PhD, FACMG

In the current era of cancer care, we’ve come to realize that non-small cell lung cancer is a disease of the genome. And now that advances in genomic profiling have enabled the identification of emerging biomarkers such as KRAS G12C oncologist Dr. Alex Spira and pathologist Dr. John Longshore are here to give us a closer look at the guideline recommendations for biomarker testing as well as best practices for overcoming real-world issues.

© 2020 Amgen Inc. All rights reserved. USA-510-80117 10/2020

Just a single point mutation in the beta-globin gene drives a complex, unrelenting condition characterized by vaso-occlusion, chronic hemolysis, and chronic anemia called hemoglobin S polymerization, as explained here.

P-UNB-US-00553 V1

Host: Jennifer Caudle, DO

Guest: Antonio Anzueto, MD

We know the burden that chronic obstructive pulmonary disease (COPD) has on our patients, but have you considered that just one moderate exacerbation increased the risk of a future hospitalization for a severe COPD exacerbation.1 This elevates the importance of why we need to be proactive in our treatment choices. Here to walk us through that data and treatment options for patients with COPD is Dr Antonio Anzueto.

*Data from a UK population-based study of ~100,000 patients with COPD (up to 10 years of follow-up). Severe exacerbations were defined as those requiring hospitalization and moderate exacerbations were defined as those managed outside the hospital.

Reference:

1. Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464-471.